CompletedInterventionalPhase 3Updated May 20, 2008
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) | NCT01671280 | Trialant
CompletedObservationalUpdated Apr 26, 2017
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Drug Use Investigation Of Azithromycin Iv
ClinicalTrials.gov ID
NCT01671280
Lead Sponsor
PfizerINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
403Actual
Last Update Posted
Apr 26, 2017Actual
Start Date
Sep 20, 2012Actual
Primary Completion Date
Apr 22, 2016Actual
Completion Date
Apr 22, 2016Actual
Official Title
Drug Use Investigation Of Azithromycin Iv
Brief Summary
To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice
Pneumonia
Pelvic Inflammatory Disease
Azithromycin IV
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or Female patients who are prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.
Exclusion Criteria:
Subjects who have been prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.